Drugs / Rineterkib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04097821 | Sep 2019 → May 2023 | myelofibrosis | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rineterkib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04097821 ↗ |
| Route | Oral | “100 mg capsule for oral use” NCT04097821 ↗ |